ABSI Stock Catalyst: Absci Corp Announces Interim Phase 1 Data from HEADLINE™ Trial of ABS-201

Jun 24, 2026 · 6:36am ET

Company revealed results on June 24, 2026.

Max move

+47.0%

High of day $11.00

Sparker timei

6:36am ET

ABSI · Jun 24, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Absci Corporation, a Nasdaq-listed biotechnology firm, announced on June 24, 2026, interim Phase 1 data from the HEADLINE™ Trial of ABS-201, an investigational anti-prolactin receptor antibody.

The announcement included details of a recent equity transaction where the company issued 13,495,277 shares at $7.41 per share, totaling $100 million. This transaction was documented in an SEC filing.

As of the latest company context, Absci Corp has 133,281,157 shares in free float.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time ABSI sparks.

Download Sniper App →

Catch the next ABSI-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →